Natco Pharma jumps on US top court stance

Natco Pharma surges 6 percent after US Supreme Court Chief Justice John Roberts denied a request by Teva Pharmaceutical Industries to stay a lower-court ruling in a patent case that favoured the developers of generic versions of Teva's multiple sclerosis drug.

The decision could help pave the way for generic competitors of Teva's Copaxone drug, including Natco, to go on the market soon.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • RBI must keep a strict vigil on private debt inflows

    A little over a year ago, RBI governor Raghuram Rajan had observed that central banks of the developed world were excessively liberal with printing mo

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Tushar Gandhi

When too little could mean too late

The calamity in Jammu and Kashmir has once again shown ...

Kuruvilla Pandikattu SJ

Genuine spirituality means true humanity

Every religion promises salvation to its followers. Rarely do we ...

Gautam Gupta

Moral policing is the need of the hour

Recently, when Deepika Padukone raised her voice against an objectionable ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture